Actinium Pharmaceuticals Inc (ATNM) Live Share Price, Invest From India

Actinium Pharmaceuticals Inc Stock Performance

as on March 31, 2026 at 4:12 am IST

Day's Low
Day's High
$1.00
Day's Price Range
$1.03
$1.02
1.96%
Downside
0.98%
Upside
52 Week's Low
52 Week's High
$1.01
52-Week Price Range
$1.95
$1.02
0.98%
Downside
90.73%
Upside

Actinium Pharmaceuticals Inc share price movements today

Previous Close: $1.03
Open: $1.01
Volume: 552.6K
Day's Low - High: $1.00 - $1.03
52 Week Low - High: $1.01 - $1.95

Actinium Pharmaceuticals Inc Historical Returns

1 Month Return: -9.65 %
3 Month Return: -26.95 %
1 Year Return: -43.09 %
3 Year Return: -88.74 %
5 Year Return: -86.55 %

Actinium Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Actinium Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$32.1M

EPS (TTM)

-1.08

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-37.1M

Revenue (TTM)

90.0K

Profit Margin

0.00%

Return On Equity TTM

-133.09%

Actinium Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Actinium Pharmaceuticals Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Actinium Pharmaceuticals Inc	BUY	$32.1M	-86.55%	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$42.1B	134.86%	136.79	8.45%
Vertex Pharmaceuticals Incorporated	BUY	$110.0B	103.33%	28.25	32.94%
Beone Medicines Ltd	NA	$32.5B	NA	115.05	5.37%
Regeneron Pharmaceuticals, Inc.	BUY	$78.0B	56.74%	17.79	31.41%

Stock Returns calculator for Actinium Pharmaceuticals Inc Stock including INR - Dollar returns

The Actinium Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Actinium Pharmaceuticals Inc investment value today

Current value as on today

₹62,448

Returns

-₹37,552

(-37.55%)

Returns from Actinium Pharmaceuticals Inc Stock

-₹43,646 (-43.65%)

Dollar Impact

₹6,094 (+6.09%)

Analyst Recommendation on Actinium Pharmaceuticals Inc Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Actinium Pharmaceuticals Inc. Average target price of $5

Actinium Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Actinium Pharmaceuticals Inc.

What analysts predicted

79.6%UPSIDE

Target Price

Current Price

$1.02

Analyzed by

12 Analysts

Target

$5.00

Actinium Pharmaceuticals Inc target price $5, a slight upside of 79.6% compared to current price of $1.02. According to 12 analysts rating.

Actinium Pharmaceuticals Inc Stock’s Investor Sentiment and Interest

Search interest for Actinium Pharmaceuticals Inc Stock has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.

Time period: February 28, 2026 to March 30, 2026

Change:-63% versus previous 30 day period

Actinium Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	-	0	-	-	-	0	-	-	0
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-15	-14	-10	-9	-12	-12	-7	-16	-7	-5
EBITDA	-14	-13	-10	-9	-11	-11	-6	-15	-6	-4
Interest Expense	0	-	0	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-15	-13	-9	-8	-11	-11	-6	-15	-6	-5
Income Tax Expense	0	0	0	0	-	-11	-	-	-	-
Net Income	-15	-13	-9	-8	-11	-11	-6	-15	-6	-5
Net Profit Margin	0.00%	0.00%	-11511.11%	0.00%	0.00%	0.00%	-821.23%	0.00%	0.00%	-5701.11%

Actinium Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-	0	1	1	0	-
Gross Profit	0	0	0	0	0	0	0	1	0	0
Operating Income	-24	-26	-26	-23	-22	-22	-24	-34	-51	-42
EBITDA	-24	-26	-26	-23	-21	-21	-24	-33	-51	-37
Interest Expense	0	0	0	0	-	-	0	1	-	-
Depreciation	-	-	0	0	0	0	0	0	0	0
Income Before Tax	-21	-24	-26	-23	-21	-22	-24	-33	-48	-38
Income Tax Expense	0	0	0	0	0	0	0	-1	0	-
Net Income	-21	-24	-26	-23	-21	-22	-24	-33	-48	-38
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-3571.54%	-2165.56%	-3205.53%	-60269.14%	0.00%

Actinium Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-13	-9	-8	-11	-11	-6	-15	-6	-5
Operating Cash Flow	-11	-7	-7	-7	-11	-5	-7	-5	-6
Investing Cash Flow	0	-	0	-	-	-	-	-	-
Financing Cash Flow	2	1	14	9	4	0	0	0	0
Change in Cash	-8	-6	7	1	-7	-5	-7	-5	-6

Actinium Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-24	-26	-23	-21	-22	-24	-33	-48	-38
Operating Cash Flow	-20	-21	-20	-21	-21	-20	8	-47	-33
Investing Cash Flow	0	0	0	0	0	0	0	0	0
Financing Cash Flow	15	18	16	17	76	35	23	14	29
Change in Cash	-5	-3	-3	-4	54	14	31	-32	-3

Insights on Actinium Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -15.93M → -5.13M (in $), with an average increase of 82.9% per quarter
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 62.6% return, outperforming this stock by 151.3%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 18.2% return, outperforming this stock by 61.3%
NEGATIVE IMPACT
Price Dip
In the last 3 years, ATNM stock has moved down by -88.7%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 810.0K → 90.0K (in $), with an average decrease of 88.9% per quarter

About Actinium Pharmaceuticals Inc

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o

Organisation	Actinium Pharmaceuticals Inc
Headquarters	100 Park Avenue, New York, NY, United States, 10017
Industry	Health Technology
CEO	Mr. Sandesh C. Seth M.B.A., M.S.
E-voting on shares	Click here to vote

Key Management of Actinium Pharmaceuticals Inc

Name	Title
Ms. Lynn M. Bodarky M.B.A.	Chief Business Officer
Dr. Madhuri Vusirikala M.D.	Vice President of Clinical Development BMT & Cellular Therapy
Mr. Sandesh C. Seth M.B.A., M.S.	CEO, Principal Financial Officer & Chairman
Dr. Paul Diamond Esq., Ph.D.	Vice President of Patent & Legal Counsel
Ms. Jenny Hsieh	Chief Strategy Officer

FAQs

What is Actinium Pharmaceuticals Inc share price today?

Actinium Pharmaceuticals Inc share price today is $1.02 as on March 30, 2026 at 10:42 pm IST. Actinium Pharmaceuticals Inc share today touched a day high of $1.03 and a low of $1.

What is the 52 week high and 52 week low for Actinium Pharmaceuticals Inc share?

Actinium Pharmaceuticals Inc share touched a 52 week high of $1.95 on June 10, 2025 and a 52 week low of $1.01 on March 27, 2026. Actinium Pharmaceuticals Inc stock price today i.e. March 30, 2026 at 10:42 pm IST is trending at $1.02,which is 47.57% down from its 52 week high and 0.99% up from its 52 week low.

What is Actinium Pharmaceuticals Inc's market capitalisation today?

Actinium Pharmaceuticals Inc market capitalisation is $0.00T as on March 30, 2026 at 10:42 pm IST.

How to invest in Actinium Pharmaceuticals Inc Stock (ATNM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Actinium Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Actinium Pharmaceuticals Inc Shares that will get you 1.4706 shares as per Actinium Pharmaceuticals Inc share price of $1.02 per share as on March 30, 2026 at 10:42 pm IST.

What is the minimum amount required to buy Actinium Pharmaceuticals Inc Stock (ATNM) from India?

Indian investors can start investing in Actinium Pharmaceuticals Inc (ATNM) shares with as little as ₹94.702 or $1 (as of March 30, 2026 at 10:42 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹947.02 in Actinium Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on March 30, 2026 at 10:42 pm IST). Based on Actinium Pharmaceuticals Inc share’s latest price of $1.02 as on March 30, 2026 at 10:42 pm IST, you will get 9.8039 shares of Actinium Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Actinium Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Actinium Pharmaceuticals Inc stock has given -86.55% share price returns and 29.05% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?